Antithymocyte immunoglobulin
Also known as: Anti-thymocyte globulin ATG
Therapeutic Indications
Antithymocyte immunoglobulin is indicated for:
Prophylaxis of graft rejection
Irrespective of gender only Adults (18 years old or older)
For this indication, the medical literature mentions below treatments (click for details):
Treatment 1: Intravenous - 1.0-2.5 mg/kg once daily
Steroid resistant graft rejection
Irrespective of gender only Adults (18 years old or older)
For this indication, the medical literature mentions below treatments (click for details):
Treatment 1: Intravenous - 1.5 mg/kg once daily
Contraindications
Active ingredient Antithymocyte immunoglobulin is contraindicated in the following cases:
Infections
No gender/age discrimination
Active acute or chronic infections, which would contraindicate any additional immunosuppression.
Antithymocyte immunoglobulin is routinely used in combination with other immunosuppressive agents. Infections (bacterial, fungal, viral and protozoal), reactivation of infection (particularly CMV) and sepsis have been reported after antithymocyte immunoglobulin administration in combination with multiple immunosuppressive agents. In rare cases, these infections have been fatal.